nodes	percent_of_prediction	percent_of_DWPC	metapath
Amphetamine—SLC22A5—dilated cardiomyopathy	0.43	1	CbGaD
Amphetamine—Lisdexamfetamine—Lisinopril—dilated cardiomyopathy	0.16	0.365	CrCrCtD
Amphetamine—Nateglinide—Lisinopril—dilated cardiomyopathy	0.142	0.326	CrCrCtD
Amphetamine—Aspartame—Lisinopril—dilated cardiomyopathy	0.135	0.309	CrCrCtD
Amphetamine—SLC22A5—Furosemide—dilated cardiomyopathy	0.0689	1	CbGbCtD
Amphetamine—CARTPT—Circadian rythm related genes—SIK1—dilated cardiomyopathy	0.00367	0.148	CbGpPWpGaD
Amphetamine—SLC22A3—Organic cation transport—SLC22A5—dilated cardiomyopathy	0.00283	0.114	CbGpPWpGaD
Amphetamine—SLC22A3—Organic cation/anion/zwitterion transport—SLC22A5—dilated cardiomyopathy	0.00192	0.0773	CbGpPWpGaD
Amphetamine—Toxic epidermal necrolysis—Spironolactone—dilated cardiomyopathy	0.00114	0.0307	CcSEcCtD
Amphetamine—Erectile dysfunction—Spironolactone—dilated cardiomyopathy	0.00101	0.0271	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Spironolactone—dilated cardiomyopathy	0.000965	0.026	CcSEcCtD
Amphetamine—TAAR1—Amine ligand-binding receptors—ADRB1—dilated cardiomyopathy	0.000882	0.0356	CbGpPWpGaD
Amphetamine—Lightheadedness—Furosemide—dilated cardiomyopathy	0.000847	0.0229	CcSEcCtD
Amphetamine—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.000826	0.0223	CcSEcCtD
Amphetamine—Accidental injury—Lisinopril—dilated cardiomyopathy	0.000803	0.0217	CcSEcCtD
Amphetamine—Viral infection—Lisinopril—dilated cardiomyopathy	0.000786	0.0212	CcSEcCtD
Amphetamine—TAAR1—Amine ligand-binding receptors—ADRB2—dilated cardiomyopathy	0.000715	0.0288	CbGpPWpGaD
Amphetamine—Irritability—Furosemide—dilated cardiomyopathy	0.000656	0.0177	CcSEcCtD
Amphetamine—Lightheadedness—Lisinopril—dilated cardiomyopathy	0.000635	0.0172	CcSEcCtD
Amphetamine—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.000621	0.0168	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Furosemide—dilated cardiomyopathy	0.000619	0.0167	CcSEcCtD
Amphetamine—CARTPT—Circadian rythm related genes—FAS—dilated cardiomyopathy	0.000602	0.0243	CbGpPWpGaD
Amphetamine—Injury—Lisinopril—dilated cardiomyopathy	0.000561	0.0151	CcSEcCtD
Amphetamine—Libido decreased—Lisinopril—dilated cardiomyopathy	0.000556	0.015	CcSEcCtD
Amphetamine—Somnolence—Spironolactone—dilated cardiomyopathy	0.000552	0.0149	CcSEcCtD
Amphetamine—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.000542	0.0146	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.000536	0.0145	CcSEcCtD
Amphetamine—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.000526	0.0142	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.000525	0.0142	CcSEcCtD
Amphetamine—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.000511	0.0138	CcSEcCtD
Amphetamine—Sweating—Furosemide—dilated cardiomyopathy	0.000508	0.0137	CcSEcCtD
Amphetamine—Urticaria—Spironolactone—dilated cardiomyopathy	0.000493	0.0133	CcSEcCtD
Amphetamine—Irritability—Lisinopril—dilated cardiomyopathy	0.000492	0.0133	CcSEcCtD
Amphetamine—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.000491	0.0132	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Lisinopril—dilated cardiomyopathy	0.000464	0.0125	CcSEcCtD
Amphetamine—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.000457	0.0123	CcSEcCtD
Amphetamine—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.000449	0.0121	CcSEcCtD
Amphetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A5—dilated cardiomyopathy	0.000444	0.0179	CbGpPWpGaD
Amphetamine—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.000425	0.0115	CcSEcCtD
Amphetamine—Dizziness—Spironolactone—dilated cardiomyopathy	0.00041	0.0111	CcSEcCtD
Amphetamine—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.00041	0.0111	CcSEcCtD
Amphetamine—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.000407	0.011	CcSEcCtD
Amphetamine—Weight decreased—Lisinopril—dilated cardiomyopathy	0.000403	0.0109	CcSEcCtD
Amphetamine—Depression—Lisinopril—dilated cardiomyopathy	0.000396	0.0107	CcSEcCtD
Amphetamine—Vomiting—Spironolactone—dilated cardiomyopathy	0.000395	0.0107	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.000394	0.0106	CcSEcCtD
Amphetamine—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.000392	0.0106	CcSEcCtD
Amphetamine—Rash—Spironolactone—dilated cardiomyopathy	0.000391	0.0106	CcSEcCtD
Amphetamine—Dermatitis—Spironolactone—dilated cardiomyopathy	0.000391	0.0106	CcSEcCtD
Amphetamine—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.000389	0.0105	CcSEcCtD
Amphetamine—Headache—Spironolactone—dilated cardiomyopathy	0.000389	0.0105	CcSEcCtD
Amphetamine—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.000386	0.0104	CcSEcCtD
Amphetamine—SLC22A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A5—dilated cardiomyopathy	0.000384	0.0155	CbGpPWpGaD
Amphetamine—Sweating—Lisinopril—dilated cardiomyopathy	0.000381	0.0103	CcSEcCtD
Amphetamine—Agitation—Furosemide—dilated cardiomyopathy	0.00038	0.0103	CcSEcCtD
Amphetamine—SLC6A4—Circadian rythm related genes—SIK1—dilated cardiomyopathy	0.000369	0.0149	CbGpPWpGaD
Amphetamine—Phenylpropanolamine—ADRB1—dilated cardiomyopathy	0.000369	0.165	CrCbGaD
Amphetamine—Nausea—Spironolactone—dilated cardiomyopathy	0.000369	0.00995	CcSEcCtD
Amphetamine—TAAR1—G alpha (s) signalling events—ADRB1—dilated cardiomyopathy	0.000364	0.0147	CbGpPWpGaD
Amphetamine—Ephedrine—ADRB2—dilated cardiomyopathy	0.000346	0.155	CrCbGaD
Amphetamine—Dry mouth—Furosemide—dilated cardiomyopathy	0.000345	0.0093	CcSEcCtD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—SCN5A—dilated cardiomyopathy	0.000343	0.0138	CbGpPWpGaD
Amphetamine—Methamphetamine—SLC22A5—dilated cardiomyopathy	0.000339	0.152	CrCbGaD
Amphetamine—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.000338	0.00912	CcSEcCtD
Amphetamine—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.000337	0.0091	CcSEcCtD
Amphetamine—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.000326	0.00881	CcSEcCtD
Amphetamine—Anorexia—Furosemide—dilated cardiomyopathy	0.000322	0.00869	CcSEcCtD
Amphetamine—Pseudoephedrine—ADRB1—dilated cardiomyopathy	0.000312	0.14	CrCbGaD
Amphetamine—Phenylpropanolamine—ADRB2—dilated cardiomyopathy	0.00031	0.139	CrCbGaD
Amphetamine—Tension—Lisinopril—dilated cardiomyopathy	0.000305	0.00822	CcSEcCtD
Amphetamine—Nervousness—Lisinopril—dilated cardiomyopathy	0.000302	0.00814	CcSEcCtD
Amphetamine—Somnolence—Furosemide—dilated cardiomyopathy	0.0003	0.0081	CcSEcCtD
Amphetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A5—dilated cardiomyopathy	0.000299	0.012	CbGpPWpGaD
Amphetamine—Pseudoephedrine—TNF—dilated cardiomyopathy	0.000296	0.132	CrCbGaD
Amphetamine—TAAR1—G alpha (s) signalling events—ADRB2—dilated cardiomyopathy	0.000295	0.0119	CbGpPWpGaD
Amphetamine—Decreased appetite—Furosemide—dilated cardiomyopathy	0.000294	0.00792	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.000292	0.00787	CcSEcCtD
Amphetamine—Fatigue—Furosemide—dilated cardiomyopathy	0.000291	0.00786	CcSEcCtD
Amphetamine—Tremor—Lisinopril—dilated cardiomyopathy	0.000291	0.00785	CcSEcCtD
Amphetamine—Constipation—Furosemide—dilated cardiomyopathy	0.000289	0.0078	CcSEcCtD
Amphetamine—Angioedema—Lisinopril—dilated cardiomyopathy	0.000284	0.00766	CcSEcCtD
Amphetamine—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.000276	0.00745	CcSEcCtD
Amphetamine—Palpitations—Lisinopril—dilated cardiomyopathy	0.000274	0.00741	CcSEcCtD
Amphetamine—Urticaria—Furosemide—dilated cardiomyopathy	0.000268	0.00724	CcSEcCtD
Amphetamine—Body temperature increased—Furosemide—dilated cardiomyopathy	0.000267	0.00721	CcSEcCtD
Amphetamine—Abdominal pain—Furosemide—dilated cardiomyopathy	0.000267	0.00721	CcSEcCtD
Amphetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A5—dilated cardiomyopathy	0.000265	0.0107	CbGpPWpGaD
Amphetamine—Chest pain—Lisinopril—dilated cardiomyopathy	0.000264	0.00713	CcSEcCtD
Amphetamine—Anxiety—Lisinopril—dilated cardiomyopathy	0.000263	0.00711	CcSEcCtD
Amphetamine—Pseudoephedrine—ADRB2—dilated cardiomyopathy	0.000262	0.117	CrCbGaD
Amphetamine—Dry mouth—Lisinopril—dilated cardiomyopathy	0.000258	0.00698	CcSEcCtD
Amphetamine—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.000253	0.00684	CcSEcCtD
Amphetamine—Infection—Lisinopril—dilated cardiomyopathy	0.000252	0.00679	CcSEcCtD
Amphetamine—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000249	0.00672	CcSEcCtD
Amphetamine—Tachycardia—Lisinopril—dilated cardiomyopathy	0.000247	0.00668	CcSEcCtD
Amphetamine—SLC6A4—Monoamine Transport—AGT—dilated cardiomyopathy	0.000246	0.00994	CbGpPWpGaD
Amphetamine—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.000245	0.00661	CcSEcCtD
Amphetamine—DRD2—Monoamine GPCRs—ADRB1—dilated cardiomyopathy	0.000245	0.00987	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—RYR2—dilated cardiomyopathy	0.000244	0.00984	CbGpPWpGaD
Amphetamine—Asthenia—Furosemide—dilated cardiomyopathy	0.000242	0.00654	CcSEcCtD
Amphetamine—Anorexia—Lisinopril—dilated cardiomyopathy	0.000242	0.00652	CcSEcCtD
Amphetamine—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000231	0.00624	CcSEcCtD
Amphetamine—Insomnia—Lisinopril—dilated cardiomyopathy	0.000229	0.00619	CcSEcCtD
Amphetamine—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000226	0.0061	CcSEcCtD
Amphetamine—DRD2—Circadian rythm related genes—SIK1—dilated cardiomyopathy	0.000226	0.00911	CbGpPWpGaD
Amphetamine—Somnolence—Lisinopril—dilated cardiomyopathy	0.000225	0.00608	CcSEcCtD
Amphetamine—Dizziness—Furosemide—dilated cardiomyopathy	0.000223	0.00603	CcSEcCtD
Amphetamine—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000223	0.00602	CcSEcCtD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.000222	0.00894	CbGpPWpGaD
Amphetamine—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.00022	0.00595	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000219	0.0059	CcSEcCtD
Amphetamine—Fatigue—Lisinopril—dilated cardiomyopathy	0.000218	0.0059	CcSEcCtD
Amphetamine—Constipation—Lisinopril—dilated cardiomyopathy	0.000217	0.00585	CcSEcCtD
Amphetamine—Vomiting—Furosemide—dilated cardiomyopathy	0.000215	0.0058	CcSEcCtD
Amphetamine—Rash—Furosemide—dilated cardiomyopathy	0.000213	0.00575	CcSEcCtD
Amphetamine—Dermatitis—Furosemide—dilated cardiomyopathy	0.000213	0.00574	CcSEcCtD
Amphetamine—SLC6A2—Monoamine Transport—AGT—dilated cardiomyopathy	0.000212	0.00855	CbGpPWpGaD
Amphetamine—Headache—Furosemide—dilated cardiomyopathy	0.000212	0.00571	CcSEcCtD
Amphetamine—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000207	0.00559	CcSEcCtD
Amphetamine—DRD2—Amine ligand-binding receptors—ADRB1—dilated cardiomyopathy	0.000206	0.0083	CbGpPWpGaD
Amphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.000202	0.00813	CbGpPWpGaD
Amphetamine—Urticaria—Lisinopril—dilated cardiomyopathy	0.000201	0.00543	CcSEcCtD
Amphetamine—Nausea—Furosemide—dilated cardiomyopathy	0.000201	0.00541	CcSEcCtD
Amphetamine—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.0002	0.00541	CcSEcCtD
Amphetamine—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.0002	0.00541	CcSEcCtD
Amphetamine—DRD2—Monoamine GPCRs—ADRB2—dilated cardiomyopathy	0.000198	0.008	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000193	0.00777	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000193	0.00777	CbGpPWpGaD
Amphetamine—SLC6A3—Monoamine Transport—AGT—dilated cardiomyopathy	0.000188	0.00757	CbGpPWpGaD
Amphetamine—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000187	0.00504	CcSEcCtD
Amphetamine—Asthenia—Lisinopril—dilated cardiomyopathy	0.000182	0.00491	CcSEcCtD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000179	0.00722	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—ABCC9—dilated cardiomyopathy	0.000177	0.00715	CbGpPWpGaD
Amphetamine—SLC22A3—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.000174	0.00703	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000173	0.007	CbGpPWpGaD
Amphetamine—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000173	0.00468	CcSEcCtD
Amphetamine—SLC18A2—Neuronal System—ACTN2—dilated cardiomyopathy	0.00017	0.00685	CbGpPWpGaD
Amphetamine—Dizziness—Lisinopril—dilated cardiomyopathy	0.000168	0.00452	CcSEcCtD
Amphetamine—DRD2—Amine ligand-binding receptors—ADRB2—dilated cardiomyopathy	0.000167	0.00672	CbGpPWpGaD
Amphetamine—Vomiting—Lisinopril—dilated cardiomyopathy	0.000161	0.00435	CcSEcCtD
Amphetamine—Rash—Lisinopril—dilated cardiomyopathy	0.00016	0.00431	CcSEcCtD
Amphetamine—Dermatitis—Lisinopril—dilated cardiomyopathy	0.00016	0.00431	CcSEcCtD
Amphetamine—Headache—Lisinopril—dilated cardiomyopathy	0.000159	0.00428	CcSEcCtD
Amphetamine—CYP2D6—Melatonin metabolism and effects—ADRB1—dilated cardiomyopathy	0.000158	0.00638	CbGpPWpGaD
Amphetamine—Nausea—Lisinopril—dilated cardiomyopathy	0.000151	0.00406	CcSEcCtD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000148	0.00598	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000147	0.00592	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000147	0.00592	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000141	0.00567	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000136	0.0055	CbGpPWpGaD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.000136	0.00547	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.000132	0.00533	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000132	0.00533	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.000125	0.00504	CbGpPWpGaD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.00012	0.00485	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000113	0.00455	CbGpPWpGaD
Amphetamine—SLC6A4—Monoamine Transport—TNF—dilated cardiomyopathy	0.000112	0.0045	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000107	0.00432	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—ABCC9—dilated cardiomyopathy	0.000106	0.00426	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000105	0.00425	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000104	0.0042	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000102	0.00413	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000102	0.00413	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—ACTN2—dilated cardiomyopathy	0.000101	0.00408	CbGpPWpGaD
Amphetamine—SLC6A2—Monoamine Transport—TNF—dilated cardiomyopathy	9.6e-05	0.00387	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—GJA1—dilated cardiomyopathy	9.53e-05	0.00384	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	9.53e-05	0.00384	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	9.11e-05	0.00367	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	9.08e-05	0.00366	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	8.86e-05	0.00357	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	8.86e-05	0.00357	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	8.83e-05	0.00356	CbGpPWpGaD
Amphetamine—SLC6A3—Monoamine Transport—TNF—dilated cardiomyopathy	8.51e-05	0.00343	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	8.29e-05	0.00334	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	8.29e-05	0.00334	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—IL10—dilated cardiomyopathy	8.26e-05	0.00333	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	8.24e-05	0.00332	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	8.21e-05	0.00331	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—AGT—dilated cardiomyopathy	7.94e-05	0.0032	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	7.71e-05	0.00311	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	7.53e-05	0.00304	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	7.53e-05	0.00304	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	7.47e-05	0.00301	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	7.09e-05	0.00286	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—ANKRD1—dilated cardiomyopathy	7.08e-05	0.00285	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	7e-05	0.00282	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	6.9e-05	0.00278	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	6.9e-05	0.00278	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	6.78e-05	0.00273	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—TAZ—dilated cardiomyopathy	6.65e-05	0.00268	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	6.41e-05	0.00259	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	6.38e-05	0.00257	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	6.28e-05	0.00253	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	6.11e-05	0.00246	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	6.11e-05	0.00246	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	6.05e-05	0.00244	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—FAS—dilated cardiomyopathy	6.05e-05	0.00244	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—SDHA—dilated cardiomyopathy	6.02e-05	0.00243	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ANKRD1—dilated cardiomyopathy	5.99e-05	0.00241	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	5.79e-05	0.00234	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	5.68e-05	0.00229	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—AGTR2—dilated cardiomyopathy	5.65e-05	0.00228	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—CXCL2—dilated cardiomyopathy	5.65e-05	0.00228	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—TAZ—dilated cardiomyopathy	5.63e-05	0.00227	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	5.49e-05	0.00222	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—CXCR3—dilated cardiomyopathy	5.25e-05	0.00212	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	5.25e-05	0.00212	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—SDHA—dilated cardiomyopathy	5.09e-05	0.00205	CbGpPWpGaD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	5.04e-05	0.00203	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PSEN2—dilated cardiomyopathy	5.01e-05	0.00202	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	4.88e-05	0.00197	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	4.72e-05	0.0019	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	4.7e-05	0.00189	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	4.49e-05	0.00181	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	4.49e-05	0.00181	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—AGT—dilated cardiomyopathy	4.49e-05	0.00181	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CXCL2—dilated cardiomyopathy	4.45e-05	0.00179	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—AGTR2—dilated cardiomyopathy	4.45e-05	0.00179	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—RAC1—dilated cardiomyopathy	4.26e-05	0.00172	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	4.18e-05	0.00168	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CXCR3—dilated cardiomyopathy	4.14e-05	0.00167	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—AGT—dilated cardiomyopathy	4.07e-05	0.00164	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	4.05e-05	0.00163	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	4.03e-05	0.00163	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—ADRB1—dilated cardiomyopathy	4.01e-05	0.00162	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—RAF1—dilated cardiomyopathy	3.87e-05	0.00156	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	3.83e-05	0.00154	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—FAS—dilated cardiomyopathy	3.7e-05	0.00149	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	3.46e-05	0.00139	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ANKRD1—dilated cardiomyopathy	3.45e-05	0.00139	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—AGTR2—dilated cardiomyopathy	3.42e-05	0.00138	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—CXCL2—dilated cardiomyopathy	3.42e-05	0.00138	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—AGTR1—dilated cardiomyopathy	3.42e-05	0.00138	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	3.28e-05	0.00132	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.25e-05	0.00131	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—TAZ—dilated cardiomyopathy	3.24e-05	0.00131	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—CXCR3—dilated cardiomyopathy	3.18e-05	0.00128	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	3.15e-05	0.00127	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—ADRB1—dilated cardiomyopathy	3.08e-05	0.00124	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—AGT—dilated cardiomyopathy	3.06e-05	0.00123	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	3.01e-05	0.00121	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—SDHA—dilated cardiomyopathy	2.93e-05	0.00118	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—RAF1—dilated cardiomyopathy	2.83e-05	0.00114	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.79e-05	0.00112	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—AGTR1—dilated cardiomyopathy	2.63e-05	0.00106	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—RAC1—dilated cardiomyopathy	2.52e-05	0.00102	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—ADRB2—dilated cardiomyopathy	2.5e-05	0.00101	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	2.43e-05	0.000981	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—AGT—dilated cardiomyopathy	2.41e-05	0.000971	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—RAF1—dilated cardiomyopathy	2.3e-05	0.000929	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.08e-05	0.000838	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.94e-05	0.000782	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	1.93e-05	0.00078	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	1.93e-05	0.00078	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ANKRD1—dilated cardiomyopathy	1.93e-05	0.00078	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—AGT—dilated cardiomyopathy	1.85e-05	0.000747	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—TAZ—dilated cardiomyopathy	1.82e-05	0.000733	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	1.8e-05	0.000725	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.8e-05	0.000725	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.79e-05	0.000722	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—AGTR2—dilated cardiomyopathy	1.76e-05	0.000708	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CXCL2—dilated cardiomyopathy	1.76e-05	0.000708	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	1.74e-05	0.000702	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—RAF1—dilated cardiomyopathy	1.67e-05	0.000674	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—SDHA—dilated cardiomyopathy	1.64e-05	0.000663	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—GPX1—dilated cardiomyopathy	1.63e-05	0.000659	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CXCR3—dilated cardiomyopathy	1.63e-05	0.000658	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CD36—dilated cardiomyopathy	1.59e-05	0.000642	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—ADRB1—dilated cardiomyopathy	1.58e-05	0.000638	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	1.49e-05	0.0006	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—AGT—dilated cardiomyopathy	1.43e-05	0.000578	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	1.41e-05	0.000569	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.4e-05	0.000564	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GPX1—dilated cardiomyopathy	1.38e-05	0.000558	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—AGTR1—dilated cardiomyopathy	1.35e-05	0.000545	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CD36—dilated cardiomyopathy	1.35e-05	0.000543	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—ADRB2—dilated cardiomyopathy	1.28e-05	0.000517	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.24e-05	0.0005	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—AGT—dilated cardiomyopathy	1.21e-05	0.000489	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PSEN2—dilated cardiomyopathy	1.17e-05	0.000471	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—EGFR—dilated cardiomyopathy	1.15e-05	0.000462	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—RAC1—dilated cardiomyopathy	1.1e-05	0.000442	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—AGT—dilated cardiomyopathy	1.05e-05	0.000422	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CXCL2—dilated cardiomyopathy	1.04e-05	0.000418	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—AGTR2—dilated cardiomyopathy	1.04e-05	0.000418	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—RAC1—dilated cardiomyopathy	9.95e-06	0.000401	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CXCR3—dilated cardiomyopathy	9.65e-06	0.000389	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—AGT—dilated cardiomyopathy	9.5e-06	0.000383	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ADRB1—dilated cardiomyopathy	9.34e-06	0.000377	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—AGTR1—dilated cardiomyopathy	7.98e-06	0.000322	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GPX1—dilated cardiomyopathy	7.96e-06	0.000321	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CD36—dilated cardiomyopathy	7.76e-06	0.000313	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ADRB2—dilated cardiomyopathy	7.57e-06	0.000305	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—AGT—dilated cardiomyopathy	6.98e-06	0.000282	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—RAF1—dilated cardiomyopathy	6.6e-06	0.000266	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	6.5e-06	0.000262	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—RAC1—dilated cardiomyopathy	5.88e-06	0.000237	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—AGT—dilated cardiomyopathy	5.61e-06	0.000226	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—EGFR—dilated cardiomyopathy	4.52e-06	0.000182	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	4.47e-06	0.00018	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	4.35e-06	0.000175	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	3.92e-06	0.000158	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—RAF1—dilated cardiomyopathy	3.9e-06	0.000157	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—EGFR—dilated cardiomyopathy	2.67e-06	0.000108	CbGpPWpGaD
